Hudson Bay Capital Management
SRPT icon

Hudson Bay Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Hudson Bay Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$342K – 1650
2025
Q2 		$342K Buy
+20,000
New +$853K ﹤0.01% 1152
2017
Q1 		– Sell
-66,900
Closed -$1.83M – 902
2016
Q4 		$1.83M Sell
66,900
-124,000
-65% -$4.98M 0.04% 367
2016
Q3 		$11.7M Buy
190,900
+168,400
+748% +$5.09M 0.28% 63
2016
Q2 		$429K Buy
+22,500
New +$417K 0.01% 309

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Hudson Bay Capital Management's SRPT Position: Q1 2026 in Review

Hudson Bay Capital Management reduced its Sarepta Therapeutics (SRPT) stake by 5.5% in Q1 2026, selling an estimated $290K and leaving 260,000 shares worth $5.66M. The position accounts for 0.02% of the portfolio, ranked #476.

Hudson Bay Capital Management first reported a position in SRPT in Q2 2016 and has held it in 27 quarters since. The position peaked at $33.1M in Q3 2016. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Hudson Bay Capital Management held 260,000 shares of Sarepta Therapeutics worth $5.66M as of Q1 2026.
  • Hudson Bay Capital Management sold 15,000 Sarepta Therapeutics shares in Q1 2026, an estimated $290K.
  • Sarepta Therapeutics made up 0.02% of Hudson Bay Capital Management's portfolio in Q1 2026, its #476 holding.
  • Hudson Bay Capital Management first reported a position in Sarepta Therapeutics in Q2 2016 and has held it in 27 quarters since.
  • Hudson Bay Capital Management's Sarepta Therapeutics position peaked at $33.1M in Q3 2016.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.